Gloria S Huang1, Rebecca C Arend, Antoinette Sakaris, Tiffany M Hebert, Gary L Goldberg. 1. Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women's Health, Department of Pathology, Albert Einstein College of Medicine and Montefiore Medical Center, Albert Einstein Cancer Center, 1695 Eastchester Road, Suite 601, Bronx, NY 10461, USA. ghuang@montefiore.org
Abstract
BACKGROUND: Müllerian adenosarcoma is a rare mixed epithelial-mesenchymal tumor. An extragenital site of origin and sarcomatous overgrowth are associated with aggressive clinical behavior. CASE: We present a rare case of extragenital adenosarcoma with sarcomatous overgrowth and coexistent endometriosis. She was treated with initial cytoreductive surgery and chemotherapy. She underwent a second surgery for management of a high-grade bowel obstruction, due to pathologically confirmed recurrent intraperitoneal adenosarcoma. A complete clinical response was achieved with liposomal doxorubicin, and the patient remains disease-free eighteen months after completion of chemotherapy. CONCLUSION: Liposomal doxorubicin appears to be an active agent for the treatment of adenosarcoma with sarcomatous overgrowth. In addition, we conclude from our review of all reported cases of extragenital adenosarcoma that concurrent endometriosis may represent a favorable prognostic factor.
BACKGROUND: Müllerian adenosarcoma is a rare mixed epithelial-mesenchymal tumor. An extragenital site of origin and sarcomatous overgrowth are associated with aggressive clinical behavior. CASE: We present a rare case of extragenital adenosarcoma with sarcomatous overgrowth and coexistent endometriosis. She was treated with initial cytoreductive surgery and chemotherapy. She underwent a second surgery for management of a high-grade bowel obstruction, due to pathologically confirmed recurrent intraperitoneal adenosarcoma. A complete clinical response was achieved with liposomal doxorubicin, and the patient remains disease-free eighteen months after completion of chemotherapy. CONCLUSION: Liposomal doxorubicin appears to be an active agent for the treatment of adenosarcoma with sarcomatous overgrowth. In addition, we conclude from our review of all reported cases of extragenital adenosarcoma that concurrent endometriosis may represent a favorable prognostic factor.
Authors: C F Verschraegen; A Vasuratna; C Edwards; R Freedman; A P Kudelka; C Tornos; J J Kavanagh Journal: Oncol Rep Date: 1998 Jul-Aug Impact factor: 3.906
Authors: Martee L Hensley; Nicole Ishill; Robert Soslow; Joseph Larkin; Nadeem Abu-Rustum; Paul Sabbatini; Jason Konner; William Tew; David Spriggs; Carol A Aghajanian Journal: Gynecol Oncol Date: 2009-01-09 Impact factor: 5.482
Authors: Jenna Z Marcus; Merieme Klobocista; Rouzan G Karabakhtsian; Eric Prossnitz; Gary L Goldberg; Gloria S Huang Journal: Int J Gynecol Cancer Date: 2018-03 Impact factor: 3.437
Authors: Tito S Patrelli; Enrico M Silini; Salvatore Gizzo; Roberto Berretta; Laura Franchi; Elena Thai; Adolf Lukanovic; Giovanni B Nardelli; Alberto Bacchi Modena Journal: BMC Cancer Date: 2011-05-15 Impact factor: 4.430
Authors: Vincenzo Dario Mandato; Federica Torricelli; Valentina Mastrofilippo; Riccardo Valli; Lorenzo Aguzzoli; Giovanni Battista La Sala Journal: BMC Cancer Date: 2018-02-05 Impact factor: 4.430